May 2017: Assessment Of The Safety, Efficacy And Usability Of The Quanta SC+ Haemodialysis System

Interim results, presented at EDTA 2017, from the Post Market Clinical Follow-up (PMCF) study to assess the safety, efficacy and usability of the SC+ Haemodialysis System, reporting on the first 915 treatments completed between 30 June 2015 and 5 May 2017.



April 2017: Assessment Of The Safety, Efficacy And Usability Of The Quanta SC+ Haemodialysis System

Interim results, presented at BRS 2017, from the Post Market Clinical Follow-up (PMCF) study to assess the safety, efficacy and usability of the SC+ Haemodialysis System, reporting on the first 660 treatments completed between 30 June 2015 and 31 December 2016.



March 2017: Assessment Of The Safety, Efficacy And Usability Of The Quanta SC+ Haemodialysis System

Interim results, presented at ADC 2017, from the Post Market Clinical Follow-up (PMCF) study to assess the safety, efficacy and usability of the SC+ Haemodialysis System, reporting on the first 660 treatments completed between 30 June 2015 and 31 December 2016.



September 2016: Assessment Of The Safety, Efficacy And Usability Of The Quanta SC+ Haemodialysis System

Interim results, presented at ISHD 2016, from the Post Market Clinical Follow-up (PMCF) study to assess the safety, efficacy and usability of the SC+ Haemodialysis System, reporting on the first 255 treatments completed demonstrating adequacy of dialysis using standard treatment regimens traditionally used in clinic.



May 2016: Assessment Of The Safety, Efficacy And Usability Of The SC+ Haemodialysis System

Interim results, presented at EDTA 2016, from the Post Market Clinical Follow-up (PMCF) study to assess the safety, efficacy and usability of the SC+ Haemodialysis System, reporting on the first 77 treatments completed demonstrating adequacy of dialysis using standard treatment regimens traditionally used in clinic.



February 2016: Open Label, Single Arm First-In-Human, Pilot Initiation Study For The SC+ Haemodialysis System

Interim results, presented at ADC 2016, from the Post Market Clinical Follow-up (PMCF) study to assess the safety, efficacy and usability of the SC+ Haemodialysis System, reporting on the first 10 treatments completed demonstrating adequacy of dialysis using standard treatment regimens traditionally used in clinic.



Quanta Dialysis Technologies, Self-Care+, SelfCareplus, SC+, Travel dialysis machine